As of September 30, the company had cash and cash equivalents of approximately $27.7M.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INMB:
- Inmune Bio to Host Q3 Results Conference Call
- INmune Bio CEO to Speak at Maxim Growth Summit
- Inmune Bio’s Promising Pipeline and Strategic Positioning Support Buy Rating Despite Recent Challenges
- Inmune Bio Submits Manuscript on Alzheimer’s Trial
- INmune Bio submits Phase 2 MINDFuL trial results to npj Dementia